Appointment of Non-Executive Director

RNS Number : 5607Y

BiVictriX Therapeutics PLC

17 January 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

BiVictriX Appoints Dr Michael Kauffman as Non-Executive Director

Alderley Park, 17 January 2022 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that it has appointed Dr Michael Kauffman, M.D., Ph.D. to its Board of Directors as an Independent Non-Executive Director with immediate effect.

Dr Kauffman joins the BiVictriX Board with more than 20 years of experience in the life sciences industry, including expertise in preclinical research, clinical development, and regulatory strategy. He currently serves on the Boards of Karyopharm Therapeutics Inc ("Karyopharm"), Verastem Oncology, Kezar Life Sciences and Adicet Bio. After co-founding Karyopharm, Dr Kauffman served as Chief Executive Officer for over a decade, during which time he guided the company from a discovery stage biotechnology company to a commercial stage organisation and, most recently, transitioned into the role of Senior Clinical Advisor. Prior to joining Karyopharm, Dr Kauffman was Chief Medical Officer of Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. and, before that, was President and Chief Executive officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). At Millennium Pharmaceuticals, Dr Kauffman led the development programme for Velcade^®, a first-line treatment for patients with multiple myeloma. He has also held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received his M.D. and Ph.D. from the Johns Hopkins University School of Medicine and is board certified in Internal Medicine.  

Iain Ross, Chairman of BiVictriX, commented: "We are delighted to welcome Dr Kauffman to the  BiVictriX Board. He brings a wealth of expertise in oncology drug development, having been instrumental in the approval of several oncology therapeutics. We look forward to working with him to advance the development of our Bi-Cygni® therapeutics, where his proven corporate experience and extensive network will be invaluable."

AIM Disclosures

The following information regarding the appointment of Dr. Michael Glen Kauffman (aged 58) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:

Current Directorships	Previous Directorships within the last five years
Karyopharm Therapeutics Inc.	Infinity Pharmaceuticals Incorporated
Verastem Oncology Inc.
Kezar Life Sciences Inc.
Adicet Bio Inc.

There are no further disclosures to be made under Schedule 2g of the AIM Rules for Companies.

For more information, please contact: BiVictriX Therapeutics plc Tiffany Thorn, Chief Executive Officer Iain Ross, Chairman Email: [e-mail] SP Angel Corporate Finance LLP (NOMAD and Broker) Tel: [phone] David Hignell, Caroline Rowe (Corporate Finance) Vadim Alexandre, Rob Rees (Sales and Broking) Panmure Gordon (UK) Limited (Joint Broker) Tel: [phone] Rupert Dearden/Freddy Crossley/Emma Earl Consilium Strategic Communications Mary-Jane Elliott, Genevieve Wilson, Alex Gunter Tel: [phone] Email:  [e-mail]

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at  www.bivictrix.com    

 

END

 

 

BOAFZGMMMVMGZZZ